$MD
Pediatrix Medical Group, Inc.

2017 Q4 Form 10-K Financial Statement

#000119312518045748 Filed on February 14, 2018

View on sec.gov

Income Statement

Concept 2017 Q4 2017 Q3 2017 Q2
Revenue $910.8M $869.0M $842.9M
YoY Change 9.64% 4.95% 9.22%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $584.7M $687.9M $664.4M
YoY Change -7.19% 11.8% 15.21%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $26.41M $25.12M $25.74M
YoY Change 4.59% 3.85% 27.14%
% of Gross Profit
Operating Expenses $785.1M $742.5M $721.0M
YoY Change 14.12% 10.64% 15.56%
Operating Profit $125.7M $126.4M $121.9M
YoY Change -11.96% -19.41% -17.51%
Interest Expense $19.84M $18.43M $18.54M
YoY Change 21.33% 7.05% 23.09%
% of Operating Profit 15.79% 14.58% 15.2%
Other Income/Expense, Net -$17.36M -$18.43M -$17.48M
YoY Change 17.46% 13.8% 26.13%
Pretax Income $108.3M $108.0M $104.4M
YoY Change -15.36% -23.24% -22.03%
Income Tax -$27.76M $42.12M $40.73M
% Of Pretax Income -25.62% 39.0% 39.0%
Net Earnings $136.1M $65.88M $63.70M
YoY Change 74.31% -31.74% -22.72%
Net Earnings / Revenue 14.94% 7.58% 7.56%
Basic Earnings Per Share $1.47 $0.71 $0.69
Diluted Earnings Per Share $1.46 $0.71 $0.69
COMMON SHARES
Basic Shares Outstanding 92.76M shares 92.59M shares 92.18M shares
Diluted Shares Outstanding 93.16M shares 92.88M shares 92.81M shares

Balance Sheet

Concept 2017 Q4 2017 Q3 2017 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $70.50M $59.40M $51.60M
YoY Change 5.22% -6.16% -17.44%
Cash & Equivalents $60.20M $48.40M $40.42M
Short-Term Investments $10.30M $11.00M $11.20M
Other Short-Term Assets $37.16M $60.61M $13.27M
YoY Change 168.94% 406.87% -0.85%
Inventory
Prepaid Expenses $15.58M $13.32M $12.32M
Receivables $504.0M $520.0M $480.4M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $627.2M $653.3M $557.6M
YoY Change 6.83% 13.53% 1.66%
LONG-TERM ASSETS
Property, Plant & Equipment $123.5M $114.8M $110.5M
YoY Change 19.86% 16.59% 22.89%
Goodwill $4.284B $4.118B $3.948B
YoY Change 11.41% 7.56% 12.48%
Intangibles
YoY Change
Long-Term Investments $80.70M $82.30M $86.30M
YoY Change 2.15% 4.05% 15.84%
Other Assets $91.93M $68.63M $61.72M
YoY Change 62.59% -23.93% -39.46%
Total Long-Term Assets $5.240B $5.027B $4.850B
YoY Change 10.26% 5.43% 14.84%
TOTAL ASSETS
Total Short-Term Assets $627.2M $653.3M $557.6M
Total Long-Term Assets $5.240B $5.027B $4.850B
Total Assets $5.867B $5.681B $5.407B
YoY Change 9.89% 6.3% 13.33%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $34.63M $27.34M $30.37M
YoY Change 21.63% 17.1% 8.78%
Accrued Expenses $403.4M $375.0M $289.7M
YoY Change 6.3% 10.33% 6.43%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $1.400M $29.30M $27.00M
YoY Change -93.0% 49.49% 58.82%
Total Short-Term Liabilities $531.4M $476.0M $350.1M
YoY Change 18.37% 15.24% 5.43%
LONG-TERM LIABILITIES
Long-Term Debt $1.851B $1.797B $1.746B
YoY Change 10.28% 1.58% 22.75%
Other Long-Term Liabilities $57.91M $42.28M $45.74M
YoY Change 28.18% -9.06% -21.48%
Total Long-Term Liabilities $57.91M $42.28M $45.74M
YoY Change -96.64% -9.06% -21.48%
TOTAL LIABILITIES
Total Short-Term Liabilities $531.4M $476.0M $350.1M
Total Long-Term Liabilities $57.91M $42.28M $45.74M
Total Liabilities $2.801B $2.764B $2.569B
YoY Change 8.62% 3.27% 16.07%
SHAREHOLDERS EQUITY
Retained Earnings $2.048B $1.912B $1.846B
YoY Change 14.71% 11.99% 14.6%
Common Stock $1.018B $1.004B $992.0M
YoY Change 4.41% 4.65% 4.75%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $3.066B $2.917B $2.838B
YoY Change
Total Liabilities & Shareholders Equity $5.867B $5.681B $5.407B
YoY Change 9.89% 6.3% 13.33%

Cashflow Statement

Concept 2017 Q4 2017 Q3 2017 Q2
OPERATING ACTIVITIES
Net Income $136.1M $65.88M $63.70M
YoY Change 74.31% -31.74% -22.72%
Depreciation, Depletion And Amortization $26.41M $25.12M $25.74M
YoY Change 4.59% 3.85% 27.14%
Cash From Operating Activities $181.8M $199.9M $137.6M
YoY Change 38.78% 1.94% -8.08%
INVESTING ACTIVITIES
Capital Expenditures $5.800M -$10.10M -$10.20M
YoY Change -153.21% 9.78% 15.91%
Acquisitions
YoY Change
Other Investing Activities -$195.0M -$237.6M -$2.200M
YoY Change 406.49% -55.51% -98.47%
Cash From Investing Activities -$189.1M -$247.7M -$12.30M
YoY Change 283.57% -54.42% -91.93%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 25.30M 55.70M -126.7M
YoY Change -132.15% -84.0% 13977.78%
NET CHANGE
Cash From Operating Activities 181.8M 199.9M 137.6M
Cash From Investing Activities -189.1M -247.7M -12.30M
Cash From Financing Activities 25.30M 55.70M -126.7M
Net Change In Cash 18.00M 7.900M -1.400M
YoY Change 500.0% 887.5% -61.11%
FREE CASH FLOW
Cash From Operating Activities $181.8M $199.9M $137.6M
Capital Expenditures $5.800M -$10.10M -$10.20M
Free Cash Flow $176.0M $210.0M $147.8M
YoY Change 24.03% 2.29% -6.75%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q4 us-gaap Stock Repurchase Program Authorized Amount1
StockRepurchaseProgramAuthorizedAmount1
600000000
CY2018Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
93795535 shares
CY2016Q3 md Unrecognized Tax Benefits Impact Effective Tax Rate
UnrecognizedTaxBenefitsImpactEffectiveTaxRate
10600000
CY2017Q2 dei Entity Public Float
EntityPublicFloat
4785069881
CY2014Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
47928000
CY2014Q4 us-gaap Malpractice Loss Contingency Accrual Undiscounted
MalpracticeLossContingencyAccrualUndiscounted
168369000
CY2014Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
2265566000
CY2014Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
17165000
CY2014Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
848767
CY2015Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
51572000
CY2015Q4 us-gaap Malpractice Loss Contingency Accrual Undiscounted
MalpracticeLossContingencyAccrualUndiscounted
202527000
CY2015Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
136600000
CY2015Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
2437846000
CY2015Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
18447000
CY2015Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
1129301
CY2016Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
18957000
CY2016Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
1224366000
CY2016Q4 us-gaap Assets Current
AssetsCurrent
587128000
CY2016Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
495276000
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
143708000
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
974304000
CY2016Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
407938000
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
28474000
CY2016Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
1719642000
CY2016Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
220635000
CY2016Q4 us-gaap Assets
Assets
5339400000
CY2016Q4 us-gaap Buildings And Improvements Gross
BuildingsAndImprovementsGross
26572000
CY2016Q4 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
3500000
CY2016Q4 us-gaap Capital Lease Obligations
CapitalLeaseObligations
3550000
CY2016Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
2054000
CY2016Q4 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
1496000
CY2016Q4 us-gaap Business Combination Liabilities Arising From Contingencies Amount Recognized
BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized
17300000
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
55698000
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
55698000
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
93718000 shares
CY2016Q4 us-gaap Cash Surrender Value Fair Value Disclosure
CashSurrenderValueFairValueDisclosure
15800000
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
93718000 shares
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
937000
CY2016Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
435388000
CY2016Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
231850000
CY2016Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
227836000
CY2016Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
1713500000
CY2016Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
49156000
CY2016Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
227802000
CY2016Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
1023000
CY2016Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1610000
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves
62212000
CY2016Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
4014000
CY2016Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
380594000
CY2016Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
1621000
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
13726000
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
103525000
CY2016Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
207552000
CY2016Q4 us-gaap Deferred Tax Liabilities Deferred Expense Reserves And Accruals
DeferredTaxLiabilitiesDeferredExpenseReservesAndAccruals
53771000
CY2016Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
203292000
CY2016Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
871821000
CY2016Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
668529000
CY2016Q4 us-gaap Fixtures And Equipment Gross
FixturesAndEquipmentGross
213521000
CY2016Q4 us-gaap Goodwill
Goodwill
3845157000
CY2016Q4 us-gaap Held To Maturity Securities Current
HeldToMaturitySecuritiesCurrent
11286000
CY2016Q4 us-gaap Held To Maturity Securities Debt Maturities After Five Through Ten Years Net Carrying Amount
HeldToMaturitySecuritiesDebtMaturitiesAfterFiveThroughTenYearsNetCarryingAmount
8970000
CY2016Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
1400000
CY2016Q4 us-gaap Held To Maturity Securities Debt Maturities After One Through Five Years Net Carrying Amount
HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount
70005000
CY2016Q4 us-gaap Held To Maturity Securities Noncurrent
HeldToMaturitySecuritiesNoncurrent
78975000
CY2016Q4 us-gaap Interest Payable Current
InterestPayableCurrent
4511000
CY2016Q4 us-gaap Land
Land
6683000
CY2016Q4 us-gaap Liabilities
Liabilities
2578633000
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5339400000
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
448949000
CY2016Q4 us-gaap Long Term Debt
LongTermDebt
1698744000
CY2016Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
20000000
CY2016Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
22054000
CY2016Q4 us-gaap Malpractice Loss Contingency Accrual Undiscounted Current
MalpracticeLossContingencyAccrualUndiscountedCurrent
28972000
CY2016Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1678744000
CY2016Q4 us-gaap Long Term Line Of Credit
LongTermLineOfCredit
783500000
CY2016Q4 us-gaap Malpractice Loss Contingency Accrual Undiscounted Noncurrent
MalpracticeLossContingencyAccrualUndiscountedNoncurrent
173080000
CY2016Q4 us-gaap Malpractice Loss Contingency Accrual Undiscounted
MalpracticeLossContingencyAccrualUndiscounted
202052000
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
50950000
CY2016Q4 us-gaap Other Assets Current
OtherAssetsCurrent
13817000
CY2016Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
130000000
CY2016Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
56543000
CY2016Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
45174000
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2016Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2016Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
11051000
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
103068000
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
246776000
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
1785526000
CY2016Q4 us-gaap Self Insurance Reserve Current
SelfInsuranceReserveCurrent
128100000
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
66.98
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
946329 shares
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
410286 shares
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
28.33
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
2760767000
CY2016Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
2760767000
CY2016Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
9469000
CY2016Q4 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
14756000
CY2016Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
1224366
CY2016Q4 md Money Market Funds At Fair Value
MoneyMarketFundsAtFairValue
12400000
CY2016Q4 md Debt Instrument Carrying Amount Non Current
DebtInstrumentCarryingAmountNonCurrent
1693500000
CY2016Q4 md Accounts Payable And Accrued Liabilities Excluding Accrued Income Taxes Current
AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent
407938000
CY2016Q4 md Debt Instrument Carrying Amount Current
DebtInstrumentCarryingAmountCurrent
20000000
CY2016Q4 md Unamortized Debt Issuance Expense Current
UnamortizedDebtIssuanceExpenseCurrent
0
CY2016Q4 md Accrued Professional Liability
AccruedProfessionalLiability
74000000
CY2016Q4 md Unamortized Debt Issuance Expense Noncurrent
UnamortizedDebtIssuanceExpenseNoncurrent
14756000
CY2016Q4 md Accrued Payroll Taxes And Benefits Current
AccruedPayrollTaxesAndBenefitsCurrent
67830000
CY2016Q4 md Long Term Debt And Capital Lease Obligations Excluding Long Term Line Of Credit
LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit
900128000
CY2016Q4 md Accrued Contingent Consideration Liability Current
AccruedContingentConsiderationLiabilityCurrent
6566000
CY2017Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
92007000
CY2017Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
1286035000
CY2017Q4 us-gaap Assets Held For Sale Not Part Of Disposal Group Current
AssetsHeldForSaleNotPartOfDisposalGroupCurrent
23500000
CY2017Q4 us-gaap Assets Held For Sale Not Part Of Disposal Group Current Other
AssetsHeldForSaleNotPartOfDisposalGroupCurrentOther
22500000
CY2017Q4 us-gaap Assets Current
AssetsCurrent
627235000
CY2017Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
503999000
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
169624000
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1017328000
CY2017Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
438017000
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
34632000
CY2017Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
1790034000
CY2017Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
225429000
CY2017Q4 us-gaap Assets
Assets
5867278000
CY2017Q4 us-gaap Buildings And Improvements Gross
BuildingsAndImprovementsGross
33024000
CY2017Q4 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
18600000
CY2017Q4 us-gaap Capital Lease Obligations
CapitalLeaseObligations
1826000
CY2017Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
1401000
CY2017Q4 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
425000
CY2017Q4 us-gaap Capital Leases Future Minimum Payments Due In Three Years
CapitalLeasesFutureMinimumPaymentsDueInThreeYears
113000
CY2017Q4 us-gaap Business Acquisition Equity Interest Issued Or Issuable Value Assigned
BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned
2700000
CY2017Q4 us-gaap Business Acquisition Purchase Price Allocation Goodwill Expected Tax Deductible Amount
BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount
159500000
CY2017Q4 us-gaap Business Combination Liabilities Arising From Contingencies Amount Recognized
BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized
30500000
CY2017Q4 us-gaap Capital Leases Future Minimum Payments Due In Four Years
CapitalLeasesFutureMinimumPaymentsDueInFourYears
74000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
60200000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
80200000
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
93721000 shares
CY2017Q4 us-gaap Capital Leases Future Minimum Payments Due Current
CapitalLeasesFutureMinimumPaymentsDueCurrent
1401000
CY2017Q4 us-gaap Cash Surrender Value Fair Value Disclosure
CashSurrenderValueFairValueDisclosure
15600000
CY2017Q4 us-gaap Capital Leases Future Minimum Payments Due In Two Years
CapitalLeasesFutureMinimumPaymentsDueInTwoYears
238000
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
93721000 shares
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
937000
CY2017Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
294058000
CY2017Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
163709000
CY2017Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
161094000
CY2017Q4 us-gaap Decrease In Unrecognized Tax Benefits Is Reasonably Possible
DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible
1100000
CY2017Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
1860500000
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
28569000
CY2017Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
147797000
CY2017Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
4150000
CY2017Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
970000
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves
45454000
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
2615000
CY2017Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
258618000
CY2017Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
685000
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
7975000
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
80056000
CY2017Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
132964000
CY2017Q4 us-gaap Deferred Tax Liabilities Deferred Expense Reserves And Accruals
DeferredTaxLiabilitiesDeferredExpenseReservesAndAccruals
31290000
CY2017Q4 us-gaap Liabilities
Liabilities
2800824000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5867278000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
531425000
CY2017Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
266753000
CY2017Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
67514000
CY2017Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
51069000
CY2017Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
44357000
CY2017Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
56636000
CY2017Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
62669000
CY2017Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
906681000
CY2017Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
639928000
CY2017Q4 us-gaap Fixtures And Equipment Gross
FixturesAndEquipmentGross
253453000
CY2017Q4 us-gaap Goodwill
Goodwill
4283963000
CY2017Q4 us-gaap Held To Maturity Securities Current
HeldToMaturitySecuritiesCurrent
10292000
CY2017Q4 us-gaap Held To Maturity Securities Debt Maturities After Five Through Ten Years Net Carrying Amount
HeldToMaturitySecuritiesDebtMaturitiesAfterFiveThroughTenYearsNetCarryingAmount
2121000
CY2017Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
1200000
CY2017Q4 us-gaap Held To Maturity Securities Debt Maturities After One Through Five Years Net Carrying Amount
HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount
78561000
CY2017Q4 us-gaap Held To Maturity Securities Noncurrent
HeldToMaturitySecuritiesNoncurrent
80682000
CY2017Q4 us-gaap Insurance Settlements Receivable
InsuranceSettlementsReceivable
18900000
CY2017Q4 us-gaap Interest Payable Current
InterestPayableCurrent
4495000
CY2017Q4 us-gaap Land
Land
6683000
CY2017Q4 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
200000
CY2017Q4 us-gaap Line Of Credit Facility Remaining Borrowing Capacity
LineOfCreditFacilityRemainingBorrowingCapacity
889300000
CY2017Q4 us-gaap Long Term Debt
LongTermDebt
1846133000
CY2017Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
1401000
CY2017Q4 us-gaap Malpractice Loss Contingency Accrual Undiscounted Current
MalpracticeLossContingencyAccrualUndiscountedCurrent
37912000
CY2017Q4 us-gaap Long Term Line Of Credit
LongTermLineOfCredit
1110500000
CY2017Q4 us-gaap Malpractice Loss Contingency Accrual Undiscounted Noncurrent
MalpracticeLossContingencyAccrualUndiscountedNoncurrent
212274000
CY2017Q4 us-gaap Malpractice Loss Contingency Accrual Undiscounted
MalpracticeLossContingencyAccrualUndiscounted
250187000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
9934000
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
53618000
CY2017Q4 us-gaap Other Assets Current
OtherAssetsCurrent
37160000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
16633000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
105272000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
24178000
CY2017Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
116000000
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
91934000
CY2017Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
57905000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
34337000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
8125000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
12065000
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2017Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
15584000
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
123536000
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
293160000
CY2017Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
20000000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
2048189000
CY2017Q4 us-gaap Self Insurance Reserve Current
SelfInsuranceReserveCurrent
138500000
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
60.21
CY2017Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
6400000
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
1041034 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
6400000
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
246342 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
27.51
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
246342 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
27.51
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
3066454000
CY2017Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
3066454000
CY2017Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
10972000
CY2017Q4 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
14367000
CY2017Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
1286035
CY2017Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
10700000
CY2017Q4 md Money Market Funds At Fair Value
MoneyMarketFundsAtFairValue
9200000
CY2017Q4 md Purchase Consideration Liability
PurchaseConsiderationLiability
1000000
CY2017Q4 md Accounts Payable And Accrued Liabilities Excluding Accrued Income Taxes Current
AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent
438017000
CY2017Q4 md Accrued Professional Liability
AccruedProfessionalLiability
111700000
CY2017Q4 md Accrued Payroll Taxes And Benefits Current
AccruedPayrollTaxesAndBenefitsCurrent
75672000
CY2017Q4 md Long Term Debt And Capital Lease Obligations Excluding Long Term Line Of Credit
LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit
740923000
CY2017Q4 md Accrued Contingent Consideration Liability Current
AccruedContingentConsiderationLiabilityCurrent
6259000
CY2015 us-gaap Adjustments To Additional Paid In Capital Tax Effect From Share Based Compensation
AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation
11583000
CY2015 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
32100000
CY2015 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
32129000
CY2015 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
1541000
CY2015 us-gaap Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net
AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet
11600000
CY2015 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
42000000
CY2015 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1800000
CY2015 us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
3135000
CY2015 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
3644000
CY2015 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
168596000
CY2015 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
20948000
CY2015 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
39700000
CY2015 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
12866000
CY2015 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
14494000
CY2015 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
1628000
CY2015 us-gaap Depreciation
Depreciation
22200000
CY2015 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
64228000
CY2015 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.3776 pure
CY2015 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.58
CY2015 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.3500 pure
CY2015 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.0029 pure
CY2015 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
-0.0041 pure
CY2015 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.61
CY2015 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0297 pure
CY2015 us-gaap Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
11583000
CY2015 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.0034 pure
CY2015 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.0043 pure
CY2015 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
181462000
CY2015 us-gaap Health Care Organization Revenue
HealthCareOrganizationRevenue
2779996000
CY2015 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
305915000
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
539729000
CY2015 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
181005000
CY2015 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-7874000
CY2015 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-4101000
CY2015 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-98000
CY2015 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
55391000
CY2015 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-2654000
CY2015 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
883000 shares
CY2015 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
3127000
CY2015 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
204038000
CY2015 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
4905000
CY2015 us-gaap Interest Expense
InterestExpense
23110000
CY2015 us-gaap Investment Income Net
InvestmentIncomeNet
1844000
CY2015 us-gaap Interest Paid Net
InterestPaidNet
20367000
CY2015 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
31600000
CY2015 us-gaap Malpractice Loss Contingency Claims Incurred In Period
MalpracticeLossContingencyClaimsIncurredInPeriod
1382000
CY2015 us-gaap Malpractice Loss Contingency Claims Incurred In Prior Periods
MalpracticeLossContingencyClaimsIncurredInPriorPeriods
13835000
CY2015 us-gaap Malpractice Loss Contingency Claims Incurred Net
MalpracticeLossContingencyClaimsIncurredNet
15217000
CY2015 us-gaap Malpractice Loss Contingency Period Increase Decrease
MalpracticeLossContingencyPeriodIncreaseDecrease
-2064000
CY2015 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-848000000
CY2015 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
368701000
CY2015 us-gaap Operating Expenses
OperatingExpenses
2222128000
CY2015 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
482943000
CY2015 us-gaap Net Income Loss
NetIncomeLoss
336320000
CY2015 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-629000
CY2015 us-gaap Operating Income Loss
OperatingIncomeLoss
557868000
CY2015 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-18139000
CY2015 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
1052000
CY2015 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
14190000
CY2015 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
33980000
CY2015 us-gaap Payments To Acquire Other Property Plant And Equipment
PaymentsToAcquireOtherPropertyPlantAndEquipment
27073000
CY2015 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
235051000
CY2015 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
818903000
CY2015 us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
12856000
CY2015 us-gaap Payment For Contingent Consideration Liability Operating Activities
PaymentForContingentConsiderationLiabilityOperatingActivities
1439000
CY2015 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
20128000
CY2015 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
31956000
CY2015 us-gaap Profit Loss
ProfitLoss
335691000
CY2015 us-gaap Proceeds And Excess Tax Benefit From Sharebased Compensation
ProceedsAndExcessTaxBenefitFromSharebasedCompensation
6100000
CY2015 us-gaap Proceeds From Issuance Of Senior Long Term Debt
ProceedsFromIssuanceOfSeniorLongTermDebt
750000000
CY2015 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
2121500000
CY2015 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
2156000000
CY2015 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
2171000
CY2015 us-gaap Share Based Compensation
ShareBasedCompensation
32129000
CY2015 us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
22576000
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
31600000
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
70.44
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
11300000
CY2015 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
20128000
CY2015 us-gaap Stock Issued1
StockIssued1
7800000
CY2015 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
3675000
CY2015 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
235051000
CY2015 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
1168000
CY2015 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
467000
CY2015 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
1692000
CY2015 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
93960000 shares
CY2015 us-gaap Valuation Allowances And Reserves Adjustments
ValuationAllowancesAndReservesAdjustments
-6108661
CY2015 us-gaap Valuation Allowances And Reserves Charged To Cost And Expense
ValuationAllowancesAndReservesChargedToCostAndExpense
6389195
CY2015 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
93077000 shares
CY2015 md Practice Salaries And Benefits
PracticeSalariesAndBenefits
1753505000
CY2015 md Provision Adjustment For Losses Related To Prior Year
ProvisionAdjustmentForLossesRelatedToPriorYear
-25797000
CY2015 md Provision Adjustment For Losses Related To Current Year
ProvisionAdjustmentForLossesRelatedToCurrentYear
39204000
CY2015 md Contractual Adjustments And Uncollectibles
ContractualAdjustmentsAndUncollectibles
6389195000
CY2015 md Practice Supplies And Other Operating Expenses
PracticeSuppliesAndOtherOperatingExpenses
98480000
CY2015 md Health Organization Revenue Gross
HealthOrganizationRevenueGross
8942957000
CY2015 md Malpractice Loss Contingency Provision For Losses
MalpracticeLossContingencyProvisionForLosses
13407000
CY2015 md Accrued Professional Liabilities Assumed Through Acquisition
AccruedProfessionalLiabilitiesAssumedThroughAcquisition
35968000
CY2015 md Stock Issued During Period Value Restricted Stock Acquisition Consideration
StockIssuedDuringPeriodValueRestrictedStockAcquisitionConsideration
7800000
CY2015 md Hospital Contract Administrative Fees
HospitalContractAdministrativeFees
226234000
CY2015 md Effective Income Tax Rate Continuing Operations Excluding Impact Of Tax Settlement
EffectiveIncomeTaxRateContinuingOperationsExcludingImpactOfTaxSettlement
0.3776 pure
CY2017 dei Amendment Flag
AmendmentFlag
false
CY2017 us-gaap Adjustments To Additional Paid In Capital Tax Effect From Share Based Compensation
AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation
0
CY2017 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
29600000
CY2017 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
107000 shares
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
29573000
CY2017 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
5514000
CY2017 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
68900000
CY2017 us-gaap Business Acquisition Equity Interests Issued Or Issuable Number Of Shares Issued
BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
69014 shares
CY2017 us-gaap Business Combination Contingent Consideration Arrangements Description
BusinessCombinationContingentConsiderationArrangementsDescription
The contingent consideration of $18.6 million recorded during the year ended December 31, 2017 is related to an agreement to pay an additional cash amount based on the achievement of certain performance measures for the period through June 1, 2019.
CY2017 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
2700000
CY2017 us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
684000
CY2017 us-gaap Business Combination Consideration Transferred1
BusinessCombinationConsiderationTransferred1
554000000
CY2017 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2017 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
24502000
CY2017 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
130053000
CY2017 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
20070000
CY2017 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2017 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
50700000
CY2017 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-63038000
CY2017 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-60073000
CY2017 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
2965000
CY2017 us-gaap Depreciation
Depreciation
33900000
CY2017 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
102879000
CY2017 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.2194 pure
CY2017 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
CY2017 dei Document Type
DocumentType
10-K
CY2017 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
2709000
CY2017 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.45
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.3500 pure
CY2017 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
0.0016 pure
CY2017 dei Document Period End Date
DocumentPeriodEndDate
2017-12-31
CY2017 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.47
CY2017 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0333 pure
CY2017 dei Entity Registrant Name
EntityRegistrantName
MEDNAX, INC.
CY2017 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2017 dei Entity Central Index Key
EntityCentralIndexKey
0000893949
CY2017 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
Yes
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.1706 pure
CY2017 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.0049 pure
CY2017 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.0002 pure
CY2017 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2017 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2017 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
67015000
CY2017 us-gaap Goodwill Period Increase Decrease
GoodwillPeriodIncreaseDecrease
438800000
CY2017 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
24551000
CY2017 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
73050000
CY2017 us-gaap Health Care Organization Revenue
HealthCareOrganizationRevenue
3458312000
CY2017 us-gaap Finitelived Intangible Assets Acquired1
FinitelivedIntangibleAssetsAcquired1
39400000
CY2017 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
417105000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
410422000
CY2017 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
75427000
CY2017 us-gaap Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability
IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability
-70000000
CY2017 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-7803000
CY2017 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-735000
CY2017 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
527000 shares
CY2017 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
952000
CY2017 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
90050000
CY2017 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-74600000
CY2017 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2792000
CY2017 us-gaap Interest Expense
InterestExpense
74559000
CY2017 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
511378000
CY2017 us-gaap Operating Expenses
OperatingExpenses
2978236000
CY2017 us-gaap Investment Income Net
InvestmentIncomeNet
3953000
CY2017 us-gaap Interest Paid Net
InterestPaidNet
73837000
CY2017 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
42600000
CY2017 us-gaap Line Of Credit Facility Expiration Date1
LineOfCreditFacilityExpirationDate1
2022-10-31
CY2017 us-gaap Malpractice Loss Contingency Claims Incurred In Period
MalpracticeLossContingencyClaimsIncurredInPeriod
712000
CY2017 us-gaap Malpractice Loss Contingency Claims Incurred In Prior Periods
MalpracticeLossContingencyClaimsIncurredInPriorPeriods
23143000
CY2017 us-gaap Malpractice Loss Contingency Claims Incurred Net
MalpracticeLossContingencyClaimsIncurredNet
23855000
CY2017 us-gaap Malpractice Loss Contingency Period Increase Decrease
MalpracticeLossContingencyPeriodIncreaseDecrease
18478000
CY2017 us-gaap Nature Of Operations
NatureOfOperations
<div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <b>1.&#xA0;&#xA0;&#xA0;&#xA0;General:</b></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> The principal business activity of MEDNAX, Inc. (&#x201C;MEDNAX&#x201D; or the &#x201C;Company&#x201D;) and its subsidiaries is to provide neonatal, anesthesia, radiology and teleradiology, maternal-fetal and other pediatric subspecialty physician services. The Company has contracts with affiliated business corporations or professional associations, limited liability companies and partnerships (&#x201C;affiliated professional contractors&#x201D;), which are separate legal entities that provide physician services in certain states and Puerto Rico. The Company and its affiliated professional contractors also have contracts with hospitals and other healthcare facilities to provide physician services, which include <font style="white-space:nowrap"><font style="white-space:nowrap">(i)&#xA0;fee-for-service</font></font> contracts, whereby hospitals and other customers agree, in exchange for the Company&#x2019;s services, to authorize the Company and its healthcare professionals to bill and collect the charges for medical services rendered by the Company&#x2019;s affiliated healthcare professionals, and (ii)&#xA0;administrative fee contracts, whereby the Company is assured a minimum revenue level.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> In addition to its national physician network, the Company also provides services nationwide to healthcare providers, including its own, through complementary businesses including a management services organization specializing in full-service revenue cycle management and a consulting services company.</p> </div>
CY2017 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-576613000
CY2017 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
89737000
CY2017 us-gaap Net Income Loss
NetIncomeLoss
320372000
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
480076000
CY2017 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-69654000
CY2017 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
3783000
CY2017 us-gaap Payments For Previous Acquisition
PaymentsForPreviousAcquisition
6200000
CY2017 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
3525000
CY2017 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
27723000
CY2017 us-gaap Payments To Acquire Other Property Plant And Equipment
PaymentsToAcquireOtherPropertyPlantAndEquipment
49309000
CY2017 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
70192000
CY2017 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
531696000
CY2017 us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
5449000
CY2017 us-gaap Payment For Contingent Consideration Liability Operating Activities
PaymentForContingentConsiderationLiabilityOperatingActivities
750000
CY2017 us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
-6705000
CY2017 us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
531700000
CY2017 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
23276000
CY2017 us-gaap Proceeds From Minority Shareholders
ProceedsFromMinorityShareholders
894000
CY2017 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
25410000
CY2017 us-gaap Profit Loss
ProfitLoss
320372000
CY2017 us-gaap Proceeds And Excess Tax Benefit From Sharebased Compensation
ProceedsAndExcessTaxBenefitFromSharebasedCompensation
4800000
CY2017 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
2846000000
CY2017 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
2699000000
CY2017 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
2267000
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
54.22
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
5500000
CY2017 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
-163944 shares
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
29573000
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P1Y6M0D
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
29.57
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
91730 shares
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P1Y6M0D
CY2017 us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
23035000
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
637529 shares
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
451094 shares
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
29300000
CY2017 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
23276000
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
65.00
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
64.82
CY2017 us-gaap Stock Issued1
StockIssued1
2657000
CY2017 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
1430000
CY2017 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
70192000
CY2017 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
143000
CY2017 dei Trading Symbol
TradingSymbol
MD
CY2017 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
2284000
CY2017 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
2068000
CY2017 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
92958000 shares
CY2017 us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
1500000
CY2017 us-gaap Valuation Allowances And Reserves Adjustments
ValuationAllowancesAndReservesAdjustments
-8223648
CY2017 us-gaap Valuation Allowances And Reserves Charged To Cost And Expense
ValuationAllowancesAndReservesChargedToCostAndExpense
8285317
CY2017 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Accounting Estimates and Assumptions</b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">The preparation of financial statements in conformity with accounting principles generally accepted in the United States (&#x201C;GAAP&#x201D;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions are involved in the calculation of the Company&#x2019;s allowance for contractual adjustments and uncollectibles on accounts receivable, liabilities for self- insured amounts and claims incurred but not reported related to the Company&#x2019;s professional liability risks and the fair value of goodwill. Actual results could differ from those estimates.</font></p> </div>
CY2017 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
92431000 shares
CY2017 md Practice Salaries And Benefits
PracticeSalariesAndBenefits
2337734000
CY2017 md Provision Adjustment For Losses Related To Prior Year
ProvisionAdjustmentForLossesRelatedToPriorYear
9983000
CY2017 md Provision Adjustment For Losses Related To Current Year
ProvisionAdjustmentForLossesRelatedToCurrentYear
41291000
CY2017 md Contractual Adjustments And Uncollectibles
ContractualAdjustmentsAndUncollectibles
8285317000
CY2017 md Practice Supplies And Other Operating Expenses
PracticeSuppliesAndOtherOperatingExpenses
120518000
CY2017 md Health Organization Revenue Gross
HealthOrganizationRevenueGross
11427238000
CY2017 md Malpractice Loss Contingency Provision For Losses
MalpracticeLossContingencyProvisionForLosses
51274000
CY2017 md Accrued Professional Liabilities Assumed Through Acquisition
AccruedProfessionalLiabilitiesAssumedThroughAcquisition
20716000
CY2017 md Stock Issued During Period Value Restricted Stock Acquisition Consideration
StockIssuedDuringPeriodValueRestrictedStockAcquisitionConsideration
2658000
CY2017 md Hospital Contract Administrative Fees
HospitalContractAdministrativeFees
316391000
CY2017 md Cash And Cash Equivalents Maturity Description
CashAndCashEquivalentsMaturityDescription
90
CY2017 md Number Of Physician Group Practices Acquired
NumberOfPhysicianGroupPracticesAcquired
10 Company
CY2017 md Number Of Maternalfetal Medicine Practices Acquired
NumberOfMaternalfetalMedicinePracticesAcquired
2 Company
CY2017 md Number Of Pediatric Subspecialty Practices Acquired
NumberOfPediatricSubspecialtyPracticesAcquired
2 Company
CY2017 md Number Of Radiology Practices Acquired
NumberOfRadiologyPracticesAcquired
4 Company
CY2017 md Number Of Neonatology Practices Acquired
NumberOfNeonatologyPracticesAcquired
1 Company
CY2017 md Business Combination Contingent Consideration Arrangements Time Period
BusinessCombinationContingentConsiderationArrangementsTimePeriod
P5Y
CY2017 md Business Combination Disposition Or Assignment Restriction Period
BusinessCombinationDispositionOrAssignmentRestrictionPeriod
P3Y
CY2017 md Number Of Pediatric Multi Specialty Practices Acquired
NumberOfPediatricMultiSpecialtyPracticesAcquired
1 Company
CY2016 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2000 shares
CY2016 us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
1619000
CY2016 us-gaap Business Combination Consideration Transferred1
BusinessCombinationConsiderationTransferred1
759600000
CY2016 us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
15000000
CY2016 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
4126000
CY2017 md Effective Income Tax Rate Continuing Operations Excluding Change In Tax Rate
EffectiveIncomeTaxRateContinuingOperationsExcludingChangeInTaxRate
0.3900 pure
CY2017 md Income Tax Expense For Excess Tax Deficiencies
IncomeTaxExpenseForExcessTaxDeficiencies
200000
CY2016 us-gaap Adjustments To Additional Paid In Capital Tax Effect From Share Based Compensation
AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation
4131000
CY2016 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
34000000
CY2016 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
34000000
CY2016 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
4816000
CY2016 us-gaap Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net
AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet
4200000
CY2016 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
60300000
CY2016 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
2673000
CY2016 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
166758000
CY2016 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
4296000
CY2016 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
45200000
CY2016 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
15596000
CY2016 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
18149000
CY2016 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
2553000
CY2016 us-gaap Depreciation
Depreciation
29000000
CY2016 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
89264000
CY2016 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.3680 pure
CY2016 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.49
CY2016 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.3500 pure
CY2016 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.0048 pure
CY2016 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
0.0006 pure
CY2016 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.52
CY2016 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0294 pure
CY2016 us-gaap Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
4241000
CY2016 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.0043 pure
CY2016 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.0211 pure
CY2016 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
182354000
CY2016 us-gaap Health Care Organization Revenue
HealthCareOrganizationRevenue
3183159000
CY2016 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
372572000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
513799000
CY2016 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
175962000
CY2016 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
11617000
CY2016 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-2234000
CY2016 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-10035000
CY2016 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
34000000
CY2016 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-7405000
CY2016 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
687000 shares
CY2016 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
3185000
CY2016 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
189203000
CY2016 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
783000
CY2016 us-gaap Interest Expense
InterestExpense
63092000
CY2016 us-gaap Investment Income Net
InvestmentIncomeNet
2019000
CY2016 us-gaap Interest Paid Net
InterestPaidNet
60453000
CY2016 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
38000000
CY2016 us-gaap Malpractice Loss Contingency Claims Incurred In Period
MalpracticeLossContingencyClaimsIncurredInPeriod
766000
CY2016 us-gaap Malpractice Loss Contingency Claims Incurred In Prior Periods
MalpracticeLossContingencyClaimsIncurredInPriorPeriods
12410000
CY2016 us-gaap Malpractice Loss Contingency Claims Incurred Net
MalpracticeLossContingencyClaimsIncurredNet
13176000
CY2016 us-gaap Malpractice Loss Contingency Period Increase Decrease
MalpracticeLossContingencyPeriodIncreaseDecrease
-3452000
CY2016 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-821217000
CY2016 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
443778000
CY2016 us-gaap Operating Expenses
OperatingExpenses
2611472000
CY2016 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
381565000
CY2016 us-gaap Net Income Loss
NetIncomeLoss
324914000
CY2016 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-318000
CY2016 us-gaap Operating Income Loss
OperatingIncomeLoss
571687000
CY2016 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-57888000
CY2016 us-gaap Number Of Businesses Acquired
NumberOfBusinessesAcquired
15 Acquisition
CY2016 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-212000
CY2016 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
60976000
CY2016 us-gaap Payments To Acquire Other Property Plant And Equipment
PaymentsToAcquireOtherPropertyPlantAndEquipment
39264000
CY2016 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
61828000
CY2016 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
762302000
CY2016 us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
10740000
CY2016 us-gaap Payment For Contingent Consideration Liability Operating Activities
PaymentForContingentConsiderationLiabilityOperatingActivities
1037000
CY2016 us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
756100000
CY2016 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
22022000
CY2016 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
41325000
CY2016 us-gaap Profit Loss
ProfitLoss
324596000
CY2016 us-gaap Proceeds And Excess Tax Benefit From Sharebased Compensation
ProceedsAndExcessTaxBenefitFromSharebasedCompensation
4700000
CY2016 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
1940000000
CY2016 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
1510000000
CY2016 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
2130000
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
34000000
CY2016 us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
6849000
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
29800000
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
67.90
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
6800000
CY2016 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
22022000
CY2016 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
2258000
CY2016 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
61828000
CY2016 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
3927000
CY2016 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
301000
CY2016 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
1966000
CY2016 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
93109000 shares
CY2016 us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
-9000000
CY2016 us-gaap Valuation Allowances And Reserves Adjustments
ValuationAllowancesAndReservesAdjustments
-7368965
CY2016 us-gaap Valuation Allowances And Reserves Charged To Cost And Expense
ValuationAllowancesAndReservesChargedToCostAndExpense
7464030
CY2016 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
92422000 shares
CY2016 us-gaap Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities
UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
5644000
CY2016 md Practice Salaries And Benefits
PracticeSalariesAndBenefits
2031220000
CY2016 md Provision Adjustment For Losses Related To Prior Year
ProvisionAdjustmentForLossesRelatedToPriorYear
-25428000
CY2016 md Provision Adjustment For Losses Related To Current Year
ProvisionAdjustmentForLossesRelatedToCurrentYear
38129000
CY2017Q1 us-gaap Health Care Organization Revenue
HealthCareOrganizationRevenue
835597000
CY2016 md Contractual Adjustments And Uncollectibles
ContractualAdjustmentsAndUncollectibles
7464030000
CY2016 md Practice Supplies And Other Operating Expenses
PracticeSuppliesAndOtherOperatingExpenses
118416000
CY2016 md Malpractice Loss Contingency Provision For Losses
MalpracticeLossContingencyProvisionForLosses
12701000
CY2016 md Hospital Contract Administrative Fees
HospitalContractAdministrativeFees
272376000
CY2016 md Number Of Anesthesiology Practices Acquired
NumberOfAnesthesiologyPracticesAcquired
8 Company
CY2016 md Number Of Neonatology Practices Acquired
NumberOfNeonatologyPracticesAcquired
1 Company
CY2016 md Effective Income Tax Rate Continuing Operations Excluding Impact Of Tax Settlement
EffectiveIncomeTaxRateContinuingOperationsExcludingImpactOfTaxSettlement
0.3887 pure
CY2017Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
25614000
CY2017Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.59
CY2017Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.59
CY2016 md Health Organization Revenue Gross
HealthOrganizationRevenueGross
10374813000
CY2016 md Number Of Physician Group Practices Acquired
NumberOfPhysicianGroupPracticesAcquired
13 Company
CY2016 md Number Of Maternalfetal Medicine Practices Acquired
NumberOfMaternalfetalMedicinePracticesAcquired
1 Company
CY2016 md Number Of Pediatric Cardiology Practices Acquired
NumberOfPediatricCardiologyPracticesAcquired
1 Company
CY2016 md Number Of Thirdparty Receivables Companies Acquired
NumberOfThirdpartyReceivablesCompaniesAcquired
1 Company
CY2016 md Number Of Patient Engagement Software Company Acquired
NumberOfPatientEngagementSoftwareCompanyAcquired
1 Company
CY2016 md Number Of Pediatric Subspecialty Practices Acquired
NumberOfPediatricSubspecialtyPracticesAcquired
2 Company
CY2017Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
103765000
CY2017Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
89658000
CY2017Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
797000
CY2017Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
34967000
CY2017Q1 us-gaap Interest Expense
InterestExpense
17752000
CY2017Q1 us-gaap Investment Income Net
InvestmentIncomeNet
576000
CY2017Q1 us-gaap Operating Expenses
OperatingExpenses
729560000
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
54691000
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
106037000
CY2017Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-16379000
CY2017Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
93143000 shares
CY2017Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
92360000 shares
CY2017Q1 md Practice Salaries And Benefits
PracticeSalariesAndBenefits
572385000
CY2017Q1 md Practice Supplies And Other Operating Expenses
PracticeSuppliesAndOtherOperatingExpenses
27796000
CY2017Q1 md Deconsolidation Percentage
DeconsolidationPercentage
1.00 pure
CY2017Q1 md Sale Of Minority Interest Percentage
SaleOfMinorityInterestPercentage
0.75 pure
CY2016Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
19584000
CY2016Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.73
CY2016Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.74
CY2016Q1 us-gaap Health Care Organization Revenue
HealthCareOrganizationRevenue
752624000
CY2016Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
89950000
CY2016Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
111182000
CY2016Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
794000
CY2016Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
43411000
CY2016Q1 us-gaap Interest Expense
InterestExpense
14463000
CY2016Q1 us-gaap Investment Income Net
InvestmentIncomeNet
618000
CY2016Q1 us-gaap Operating Expenses
OperatingExpenses
628391000
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
67899000
CY2016Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-128000
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
124233000
CY2016Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-13051000
CY2016Q1 us-gaap Profit Loss
ProfitLoss
67771000
CY2016Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
93091000 shares
CY2016Q2 md Practice Supplies And Other Operating Expenses
PracticeSuppliesAndOtherOperatingExpenses
26992000
CY2016Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
92269000 shares
CY2016Q1 md Practice Salaries And Benefits
PracticeSalariesAndBenefits
491811000
CY2016Q1 md Practice Supplies And Other Operating Expenses
PracticeSuppliesAndOtherOperatingExpenses
27046000
CY2016Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
20241000
CY2016Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.89
CY2016Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.89
CY2016Q2 us-gaap Health Care Organization Revenue
HealthCareOrganizationRevenue
771759000
CY2016Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
92116000
CY2016Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
133926000
CY2016Q2 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
789000
CY2016Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
51601000
CY2016Q2 us-gaap Interest Expense
InterestExpense
15058000
CY2016Q2 us-gaap Investment Income Net
InvestmentIncomeNet
410000
CY2016Q2 us-gaap Operating Expenses
OperatingExpenses
623974000
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
82427000
CY2016Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-102000
CY2016Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
147785000
CY2016Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-13859000
CY2016Q2 us-gaap Profit Loss
ProfitLoss
82325000
CY2016Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
92945000 shares
CY2016Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
92182000 shares
CY2016Q2 md Practice Salaries And Benefits
PracticeSalariesAndBenefits
484625000
CY2017Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
25735000
CY2017Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.69
CY2017Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.69
CY2017Q2 us-gaap Health Care Organization Revenue
HealthCareOrganizationRevenue
842944000
CY2017Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
103015000
CY2017Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
104423000
CY2017Q2 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
689000
CY2017Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
40725000
CY2017Q2 us-gaap Interest Expense
InterestExpense
18535000
CY2017Q2 us-gaap Investment Income Net
InvestmentIncomeNet
365000
CY2017Q2 us-gaap Operating Expenses
OperatingExpenses
721040000
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
63698000
CY2017Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
121904000
CY2017Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-17481000
CY2017Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
92812000 shares
CY2016Q3 md Practice Supplies And Other Operating Expenses
PracticeSuppliesAndOtherOperatingExpenses
31641000
CY2016Q3 md Practice Salaries And Benefits
PracticeSalariesAndBenefits
521832000
CY2017Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
92181000 shares
CY2017Q2 md Practice Salaries And Benefits
PracticeSalariesAndBenefits
561418000
CY2017Q2 md Practice Supplies And Other Operating Expenses
PracticeSuppliesAndOtherOperatingExpenses
30872000
CY2016Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
24185000
CY2016Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.04
CY2016Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.04
CY2016Q3 us-gaap Health Care Organization Revenue
HealthCareOrganizationRevenue
828006000
CY2016Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
93457000
CY2016Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
140693000
CY2016Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
796000
CY2016Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
44272000
CY2016Q3 us-gaap Interest Expense
InterestExpense
17215000
CY2016Q3 us-gaap Investment Income Net
InvestmentIncomeNet
221000
CY2016Q3 us-gaap Operating Expenses
OperatingExpenses
671115000
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
96509000
CY2016Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-88000
CY2016Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
156891000
CY2016Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-16198000
CY2016Q3 us-gaap Profit Loss
ProfitLoss
96421000
CY2016Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
93146000 shares
CY2016Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
92604000 shares
CY2017Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
25116000
CY2017Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.71
CY2017Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.71
CY2017Q3 us-gaap Health Care Organization Revenue
HealthCareOrganizationRevenue
868951000
CY2017Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
101430000
CY2017Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
107999000
CY2017Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-240000
CY2017Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
42119000
CY2017Q3 us-gaap Interest Expense
InterestExpense
18428000
CY2017Q3 us-gaap Investment Income Net
InvestmentIncomeNet
235000
CY2017Q3 us-gaap Operating Expenses
OperatingExpenses
742519000
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
65880000
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
126432000
CY2017Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-18433000
CY2017Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
92881000 shares
CY2017Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
92589000 shares
CY2017Q3 md Practice Salaries And Benefits
PracticeSalariesAndBenefits
586476000
CY2017Q3 md Practice Supplies And Other Operating Expenses
PracticeSuppliesAndOtherOperatingExpenses
29497000
CY2016Q4 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
25254000
CY2016Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.84
CY2016Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.84
CY2016Q4 us-gaap Health Care Organization Revenue
HealthCareOrganizationRevenue
830770000
CY2016Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
97049000
CY2016Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
127998000
CY2016Q4 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
806000
CY2016Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
49919000
CY2016Q4 us-gaap Interest Expense
InterestExpense
16356000
CY2016Q4 us-gaap Investment Income Net
InvestmentIncomeNet
770000
CY2016Q4 us-gaap Operating Expenses
OperatingExpenses
687992000
CY2016Q4 us-gaap Net Income Loss
NetIncomeLoss
78079000
CY2016Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
142778000
CY2016Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-14780000
CY2016Q4 us-gaap Profit Loss
ProfitLoss
78079000
CY2016Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
93347000 shares
CY2016Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
92728000 shares
CY2016Q4 md Practice Salaries And Benefits
PracticeSalariesAndBenefits
532952000
CY2016Q4 md Practice Supplies And Other Operating Expenses
PracticeSuppliesAndOtherOperatingExpenses
32737000
CY2017Q4 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
26414000
CY2017Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.46
CY2017Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.47
CY2017Q4 us-gaap Health Care Organization Revenue
HealthCareOrganizationRevenue
910820000
CY2017Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
108895000
CY2017Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
108342000
CY2017Q4 us-gaap Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability
IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability
-70000000
CY2017Q4 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-294000
CY2017Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-27761000
CY2017Q4 us-gaap Interest Expense
InterestExpense
19844000
CY2017Q4 us-gaap Investment Income Net
InvestmentIncomeNet
2777000
CY2017Q4 us-gaap Operating Expenses
OperatingExpenses
785117000
CY2017Q4 us-gaap Net Income Loss
NetIncomeLoss
136103000
CY2017Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
125703000
CY2017Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-17361000
CY2017Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
93159000 shares
CY2017Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
92756000 shares
CY2017Q4 md Practice Salaries And Benefits
PracticeSalariesAndBenefits
617455000
CY2017Q4 md Practice Supplies And Other Operating Expenses
PracticeSuppliesAndOtherOperatingExpenses
32353000

Files In Submission

Name View Source Status
0001193125-18-045748-index-headers.html Edgar Link pending
0001193125-18-045748-index.html Edgar Link pending
0001193125-18-045748.txt Edgar Link pending
0001193125-18-045748-xbrl.zip Edgar Link pending
d463027d10k.htm Edgar Link pending
d463027dex1028.htm Edgar Link pending
d463027dex1029.htm Edgar Link pending
d463027dex1030.htm Edgar Link pending
d463027dex104.htm Edgar Link pending
d463027dex105.htm Edgar Link pending
d463027dex211.htm Edgar Link pending
d463027dex231.htm Edgar Link pending
d463027dex311.htm Edgar Link pending
d463027dex312.htm Edgar Link pending
d463027dex32.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g463027g94d84.jpg Edgar Link pending
md-20171231.xml Edgar Link completed
md-20171231.xsd Edgar Link pending
md-20171231_cal.xml Edgar Link unprocessable
md-20171231_def.xml Edgar Link unprocessable
md-20171231_lab.xml Edgar Link unprocessable
md-20171231_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending